Trials / Terminated
TerminatedNCT00276159
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase II Study of 852A Administered Subcutaneously in Patients With Hematologic Malignancies Not Responding to Standard Treatment
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
Detailed description
852A will be administered as a subcutaneous injection (SC) 2 times per week for 12 weeks (24 doses) with provisions for dose escalation or reduction based on tolerability
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Non-Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 852A | Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2. |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2006-01-13
- Last updated
- 2019-09-04
- Results posted
- 2010-05-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00276159. Inclusion in this directory is not an endorsement.